Table 1.
Baseline Characteristics
| Variable | Y90 alone (n=8) | Y90 + Sorafenib (n=7) | Total (n=15) | P-value | |
|---|---|---|---|---|---|
| Age (years) | Median | 59 | 56 | 57 | 0.30 |
| Range | 54-67 | 49-62 | 49-67 | ||
| Gender | Male | 5 | 5 | 10 | 1.0 |
| Female | 3 | 2 | 5 | ||
| Ethnicity | Caucasian | 5 | 5 | 10 | 1.0 |
| Hispanic | 2 | 2 | 4 | ||
| African-American | 1 | 0 | 1 | ||
| Etiology | HCV | 5 | 5 | 10 | 1.0 |
| Alcohol | 1 | 1 | 2 | ||
| NASH | 0 | 1 | 1 | ||
| Alcohol + NASH | 1 | 0 | 1 | ||
| PBC | 0 | 0 | 0 | ||
| Cryptogenic | 1 | 0 | 1 | ||
| Method of Diagnosis | Imaging | 5 | 6 | 11 | 1.0 |
| Biopsy | 3 | 1 | 4 | ||
| Baseline AFP (ng/mL) | Median | 13.2 | 11.9 | 11.9 | 0.60 |
| Range | 1.5-484.6 | 4.5-62.8 | 1.5-484.6 | ||
| ECOG | 0 | 5 | 5 | 10 | 1.0 |
| 1 | 2 | 2 | 4 | ||
| 2 | 1 | 0 | 1 | ||
| Child-Pugh | A | 6 | 5 | 11 | 1.0 |
| B | 2 | 2 | 4 | ||
| BCLC | A | 4 | 5 | 9 | 1.0 |
| B | 1 | 0 | 1 | ||
| C | 3 | 2 | 5 | ||
| Portal Hypertension | Absent | 0 | 1 | 1 | 0.47 |
| Present | 8 | 6 | 14 | ||
| Tumor distribution | Unilobar | 8 | 6 | 14 | 1.0 |
| Bilobar | 0 | 1 | 1 | ||
| Multiplicity | Solitary | 8 | 6 | 14 | 0.47 |
| Multifocal | 0 | 1 | 1 | ||
| UNOS stage | T1 | 0 | 1 | 1 | 0.20 |
| T2 | 8 | 5 | 13 | ||
| T3 | 0 | 1 | 1 |